The innovational device for the diagnosis of early-stage cancer by a drop of blood was invented by Chinese scientists. Malignant tumours at an early stage of development are much easier to treat. However, the cancer is extremely hard to identify in the initial phase. In 1989, scientists had discovered in the human organism heat shock proteins Hsp90α, which, presumably, can be used as cancer biomarkers.
Since then, scientists have been studying the capability of using these proteins to detected cancer (lat. Carcinoma), however, until this research, the theoretical development has not been implemented in practice.
According to the statistic, in 2015 about 90.5 million people were diagnosed with cancer in the world. The statistics are roughly increased each year by 14.1 million. About 15.7% of all deaths due to cancer. It is about 8.8 million people. In China, about 4.29 million people were identified as having cancer and about 2.8 million people died in 2015.
The researcher's team led by professor Luo Yongzhang from the School of Life Sciences at Tsinghua University in Beijing had fortunately found that a reagent test kit of Hsp90α for clinical treatment can detect various types of cancer by analyzing the drop of human blood.
Hsp90alpha is a molecular chaperone that is based inside the cell. Hsp90alpha, which is secreted by the cell, is a C-terminal reduced form and its secretion is controlled by the C-terminal EEVD motif by combining with proteins, which contain tetratricopeptide repeat domains. The level of plasma of this substance is connected with a malignancy tumour in clinical cancer patients. Furthermore, this regulatory mechanism has the function of tumour invasiveness and the capability to diagnose tumour markers in clinical application.
The team, which had been dealing with this problem since 2009, claims that it removed the artificial protein Hsp90α, which receives structural stability in the protein rearrangement. It means that scientists can create such a protein in any number and at any moment.
According to Chinese scientists, this invention was clinically tested in 8 hospitals in China involving 2347 patients. There was the world's first case of using heat shock proteins as tumor biomarkers of lung cancer. The present invention had been certified to enter the Chinese and, possibly, European market. It happened 24 years ago, as the Hsp90α protein was detected.
Scientists have been engaged in finding ways to diagnose cancer at its earliest stages during for a long time. The innovational method is quite significant for the medical diagnostics of cancer, which enables it to be diagnosed early stages and increases the chances of successful treatment. The heat shock proteins provide an opportunity to quickly diagnose the presence of malignant formations in the body of the patient. However, further treatment requires a more detailed diagnosis.